Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.
Hello,
If taking on a surge in coronavirus cases wasn’t enough, US hospitals are facing cyberattacks from Russia, which could be massively disruptive, the US is warning.
Today in healthcare news: A look at which biotech execs have sold stock as their companies develop COVID-19 treatments and vaccines, Y Combinator’s guide to spinning a company out of a university, and four biotech stocks investors should buy, according to UBS.
Biotech execs hunting for COVID-19 vaccines and treatments have raked in more than $1 billion by selling company stock this year. Here are the 27 leaders who've cashed in the most.
- Executives and board members from 14 biotech companies working on coronavirus vaccines and treatments have sold more than $1 billion in company stock this year.
- Business Insider asked Equilar, an executive-compensation-analysis firm, to tally hundreds of financial disclosures of stock sales made by company insiders.
See the full breakdown in this graphic by Andrew Dunn and Sawyer Click here>>
Y Combinator partner Jared Friedman.
Y Combinator
The top startup accelerator just released its how-to guide for scientists and academics who want to start companies. Here's what Y Combinator says all founders need to know.
Y Combinator
- Startup accelerator Y Combinator just released its first comprehensive guide for spinning scientific research out of universities and into companies, a common way many biotech startups are founded.
- Y Combinator has funded 75 companies that have come out of academia, and compiled those experiences in a comprehensive guide for potential founders with similar backgrounds.
- Business Insider got an exclusive look at the guide itself.
UBS just shared the 4 biotech stocks investors should buy now — including 2 that could soar more than 50%
- UBS on Tuesday initiated coverage on nine biotech companies.
- The analysts noted that they're optimistic about where the biotech sector will be in 2021, after a good 2019 and a promising 2020 so far.
- UBS analysts gave buy ratings to four biotech companies.
More stories we're reading:
- Nordstrom covered health insurance for furloughed workers. Now it wants them to pay it back as Americans' savings are dwindling to $0.(Business Insider)
- An inside look at the fight over Pinterest's health misinformation policy (Stat News)
- The Trump administration is getting set to announce that Medicare and Medicaid will cover COVID-19 vaccines (CNN)
- Having more than 5 coronavirus symptoms is a sign you could be at risk of a long-term case, new research shows(Business Insider)
- We just got our first look at sales of Gilead's coronavirus-fighting drug remdesivir (Business Insider)
- Dr. Fauci predicts no COVID-19 vaccine until at least January, and warns of a 'whole lot of pain' if US cases continue to surge (Business Insider)
- Lydia
Read the original article on Business Insider